ProPhase Labs Reports Financial Results for the First Quarter Ended March 31, 2014

ProPhase Labs Reports Financial Results for the First Quarter Ended March 31, 
2014 
DOYLESTOWN, PA -- (Marketwired) -- 05/12/14 --  ProPhase Labs, Inc.
(NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported net sales of
$6.2 million for the three months ended March 31, 2014 as compared to
net sales of $7.5 million for the three months ended March 31, 2013.
The Company incurred a net loss for the three months ended March 31,
2014, of ($804,000), or ($0.05) per share, compared to net income of
$290,000, or $0.02 per share, for the three months ended March 31,
2013.  
The financial results for the three months ended March 31, 2014 as
compared to three months ended March 31, 2013 reflect the net effect
of (i) a decrease of our revenues due principally to (a) industry
data suggesting there was reduction of over 12% in the incidence of
upper respiratory disorders from period to period and, as a
consequence, (b) the timing of purchases and the ultimate level of
demand for our products, (ii) an increase in research and development
expenditures of $90,000 as we seek to expand our future product
offerings to consumers, offset by (iii) a decrease in sales and
marketing expenses of $366,000 as a consequence of the fluctuation
from period to period of the timing and scope of our marketing
initiatives.  
Ted Karkus, ProPhase Labs' Chairman and CEO stated, "The 2013-2014
Cold Season resulted in a relatively weak incidence of upper
respiratory illness as compared to the 2012-2013 Cold Season.
Consequently, our retail customers managed their inventory levels
cautiously this quarter, which impacts the timing and volume of our
shipments."  
Mr. Karkus continued, "Our goals for 2014 include continuing our
successful strategy of investing in and expanding our Cold-EEZE(R)
Cold Remedy brand and product line up. We plan to introduce another
new, premium Cold-EEZE(R) product (which we expect to be available
nationally in the fall of 2014) which will utilize our popular
QuickMelt delivery form and will shorten the duration of the common
cold as well as provide consumers important additional health
benefits."  
Mr. Karkus added, "As you know, the Company's forward planning is
focused on delivering long term growth and sustainable sales revenues
by leveraging our strong brand a
wareness, our strong distribution
platform and relationships, our ability to attract capital as needed
to support our marketing and development efforts, and our deep
marketing expertise. Our long term goals include introducing products
both within and outside of the cough/cold category to capitalize on
our core capabilities and assets."  
About ProPhase Labs 
ProPhase Labs is a diversified natural health medical science
company. It is a leading marketer of the Cold-EEZE(R) Cold Remedy
brand as well as other cold relief products. Cold-EEZE(R) Cold Remedy
zinc gluconate lozenges are clinically proven to significantly reduce
the duration of the common cold. Cold-EEZE(R) Cold Remedy customers
include leading national chain, regional, specialty and local retail
stores. ProPhase Labs has several wholly owned subsidiaries including
a manufacturing unit, which consists of an FDA registered facility to
manufacture Cold-EEZE(R) Cold Remedy lozenges and fulfill other
contract manufacturing opportunities. ProPhase also owns 50% of
Phusion Laboratories, LLC ("Phusion"). Phusion licenses a
revolutionary proprietary technology that has the potential to
improve the delivery and/or efficacy of many active ingredients or
compounds. Phusion will formulate and test products to exploit market
opportunities within ProPhase's robust over-the-counter distribution
channels. For more information visit us at www.ProPhaseLabs.com.  
Except for the historical information contained herein, this document
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a
number of risks and uncertainties, including the difficulty of the
acceptance and demand for our products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in our Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and any
subsequent SEC filings. 


 
                                                                            
                    PROPHASE LABS, INC. AND SUBSIDIARIES                    
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS               
                  (in thousands, except per share amounts)                  
                                (unaudited)                                 
                                                                            
                                                   Three Months Ended       
                                             ------------------------------ 
                                             March 31, 2014  March 31, 2013 
                                             --------------  -------------- 
                                                                            
Net sales                                    $        6,171  $        7,542 
Cost of sales                                         2,191           2,203 
                                             --------------  -------------- 
Gross profit                                          3,980           5,339 
                                             --------------  -------------- 
                                                                            
Operating expenses:                                                         
  Sales and marketing                                 2,997           3,363 
  Administration                                      1,507           1,495 
  Research and development                              278             188 
                                             --------------  -------------- 
                                                      4,782           5,046 
                                             --------------  -------------- 
                                                                            
Income (loss) from operations                          (802)            293 
                                                                            
Interest income                                           -               - 
Interest expense                                         (2)             (3)
                                             --------------  -------------- 
Income (loss) before income tax                        (804)            290 
                                                                            
Income tax                                                -               - 
                                                                            
                                             --------------  -------------- 
Net income (loss)                            $         (804) $          290 
                                             ==============  ============== 
                                                                            
Basic income (loss) per share                                               
                                             --------------  -------------- 
  Net Income (loss)                          $        (0.05) $         0.02 
                                             ==============  ============== 
                                                             
               
Diluted income (loss) per share                                             
                                             --------------  -------------- 
  Net Income (loss)                          $        (0.05) $         0.02 
                                             ==============  ============== 
                                                                            
Weighted average common shares outstanding:                                 
  Basic                                              16,469          15,752 
                                             ==============  ============== 
  Diluted                                            16,469          16,199 
                                             ==============  ============== 
                                                                            
                                                                            
                                                                            
                    PROPHASE LABS, INC. AND SUBSIDIARIES                    
                  CONDENSED CONSOLIDATED BALANCE SHEET DATA                 
                               (in thousands)                               
                                 (unaudited)                                
                                                                            
                                                  March 31,     December 31,
                                                     2014           2013    
                                                -------------  -------------
                                                                            
Cash and cash equivalents                       $       5,519  $       1,638
Accounts receivable                             $       2,856  $       5,319
Inventory                                       $       2,212  $       2,521
Total current assets                            $      11,173  $      11,279
Total assets                                    $      17,267  $      17,420
                                                                            
Total current liabilities                       $       4,264  $       4,624
Other long term obligations                     $         200  $         200
Total stockholders' equity                      $      12,803  $      12,596

  
Press Only Contact 
Laura Maxey 
5W Public Relations 
Tel: (212) 452-6400 
lmaxey@5wpr.com  
Investor Contact 
Ted Karkus
Chairman and CEO
ProPhase Labs, Inc. 
(215) 345-0919 x 0 
 
 
Press spacebar to pause and continue. Press esc to stop.